[go: up one dir, main page]

ES2155048T1 - Composicion biologicamente activa. - Google Patents

Composicion biologicamente activa.

Info

Publication number
ES2155048T1
ES2155048T1 ES99927061T ES99927061T ES2155048T1 ES 2155048 T1 ES2155048 T1 ES 2155048T1 ES 99927061 T ES99927061 T ES 99927061T ES 99927061 T ES99927061 T ES 99927061T ES 2155048 T1 ES2155048 T1 ES 2155048T1
Authority
ES
Spain
Prior art keywords
biologically active
ester
polyester
active agent
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES99927061T
Other languages
English (en)
Other versions
ES2155048T3 (es
Inventor
Ake Lindahl
Hakan Hagslatt
Catharina Heiman
Rickard Bryland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioglan AB
Original Assignee
Bioglan AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioglan AB filed Critical Bioglan AB
Publication of ES2155048T1 publication Critical patent/ES2155048T1/es
Application granted granted Critical
Publication of ES2155048T3 publication Critical patent/ES2155048T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un método para la preparación de una composición biológicamente activa que comprende un agente biológicamente activo disuelto y/o dispersado en un portador no cristalino de éster y/o poliéster para el mismo, en donde una sustancia portadora de partida, o una mezcla de dos o más sustancias portadoras de partida diferentes, se somete(n) a una(s) reacción(es) química(s) tal(es) que se forme una matriz portadora liquida no cristalina de éster y/o poliéster; se añade un agente biológicamente activo, en forma sólida y/o líquida o alternativamente en forma de una solución o dispersión, a dicha matriz portadora líquida no cristalina después de que se haya(n) completado dicha(s) reacción(es) formadora(s) de éster y/o poliéster; y el agente biológicamente activo se disuelve a continuación en dicha matriz de éster y/o poliéster a una temperatura por encima de la temperatura ambiente de modo que proporcione una composición sobresaturada a temperatura ambiente.
ES99927061T 1998-05-14 1999-05-12 Composicion biologicamente activa. Expired - Lifetime ES2155048T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801704A SE9801704D0 (sv) 1998-05-14 1998-05-14 Biologically active composition

Publications (2)

Publication Number Publication Date
ES2155048T1 true ES2155048T1 (es) 2001-05-01
ES2155048T3 ES2155048T3 (es) 2006-06-16

Family

ID=20411318

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99927061T Expired - Lifetime ES2155048T3 (es) 1998-05-14 1999-05-12 Composicion biologicamente activa.

Country Status (20)

Country Link
US (1) US6537576B1 (es)
EP (1) EP1082102B1 (es)
JP (1) JP2002514587A (es)
KR (1) KR100592971B1 (es)
CN (1) CN1309553A (es)
AT (1) ATE310500T1 (es)
AU (1) AU736480B2 (es)
CA (1) CA2331527C (es)
DE (2) DE1082102T1 (es)
ES (1) ES2155048T3 (es)
GR (1) GR20010300013T1 (es)
HU (1) HUP0102426A2 (es)
IL (2) IL139576A0 (es)
NO (1) NO20005724L (es)
NZ (1) NZ508073A (es)
PL (1) PL344051A1 (es)
SE (1) SE9801704D0 (es)
TR (1) TR200003589T2 (es)
WO (1) WO1999058108A1 (es)
ZA (1) ZA200006474B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524652A (ja) * 2000-02-29 2003-08-19 ツァン，ツィエ 改良された経皮薬剤パッチ
MX2008015599A (es) * 2006-06-14 2009-03-06 Reddys Lab Ltd Dr Composiciones topicas.
US20080226698A1 (en) 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
CA2739380C (en) * 2008-10-06 2014-12-09 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
ES2981043T3 (es) 2013-02-28 2024-10-07 Journey Medical Corp Procedimiento para fabricar tosilato de glicopirrolato treo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD217989A1 (de) 1983-08-09 1985-01-30 Univ Ernst Moritz Arndt Verfahren zur herstellung einer pharmazeutischen zubereitung
US4940701A (en) 1984-01-25 1990-07-10 Beecham Group P.L.C. Topical drug release system
AR246186A1 (es) 1989-11-17 1994-07-29 Beta Pharm Co Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica.
SE9502244D0 (sv) * 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
GB2306885B (en) 1995-11-08 1999-07-14 Reckitt & Colmann Prod Ltd Supersaturated Pharmaceutical Compositions

Also Published As

Publication number Publication date
ATE310500T1 (de) 2005-12-15
NZ508073A (en) 2002-12-20
DE1082102T1 (de) 2001-09-06
NO20005724D0 (no) 2000-11-13
GR20010300013T1 (en) 2001-04-30
WO1999058108A1 (en) 1999-11-18
ZA200006474B (en) 2001-09-04
DE69928524D1 (de) 2005-12-29
EP1082102B1 (en) 2005-11-23
IL139576A (en) 2007-07-04
AU4405099A (en) 1999-11-29
SE9801704D0 (sv) 1998-05-14
HUP0102426A2 (hu) 2002-03-28
PL344051A1 (en) 2001-09-24
CN1309553A (zh) 2001-08-22
IL139576A0 (en) 2002-02-10
ES2155048T3 (es) 2006-06-16
DE69928524T2 (de) 2006-08-10
EP1082102A1 (en) 2001-03-14
JP2002514587A (ja) 2002-05-21
KR20010052348A (ko) 2001-06-25
KR100592971B1 (ko) 2006-06-23
AU736480B2 (en) 2001-07-26
TR200003589T2 (tr) 2001-03-21
NO20005724L (no) 2001-01-09
CA2331527C (en) 2010-04-13
US6537576B1 (en) 2003-03-25
CA2331527A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
ES2118677T1 (es) Una composicion que comprende un agente activo disuelto en un vehiculo vitrificante y un procedimiento para su preparacion.
TR199900353T2 (xx) Kontroll� salma sa�layan cihazlar�n yap�m� i�in y�ntem.
ES8101894A1 (es) Procedimiento de obtencion de una matriz polimerica de difu-sion
ES2171471T3 (es) Sistema para la administracion oral de desferrioxamina.
BRPI0413432A (pt) método de esterificação de amido
NO931832L (no) Fremgangsmaate og blanding for kontrollert avgivelse av biologisk aktive midler
AR004483A1 (es) Compuestos para uso en terapia que comprenden un residuo de 1,3-propano diol como agente enlazante entre el residuo de ácido graso y un residuo bioactivo, usos de dichos compuestos y medicamentos , alimentos y formulaciones para el cuidado o tratamiento de la piel que comprenden a dichos compuestos
AR012691A1 (es) Sistema terapeutico de liberacion dirigido, metodo de preparacion del mismo y metodo para la liberacion controlada de dicho sistema.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
KR930701983A (ko) 방출억제성 베라파밀 정제
MY143793A (en) Non-tabletted, chewable, individually dosed administration forms
AR018357A1 (es) Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos
PT801559E (pt) Processo para a preparacao de formas de dosagem oral contendo um antibiotico de beta-lactama
ES2155048T3 (es) Composicion biologicamente activa.
BR9909637A (pt) Processo para a produção de um tablete de uma composição particulada compactada, tablete de composição particulada compactada, e, usos de cristais ou acetato de sódio hidratado ou anidro, acetato de potássio ou misturas dos mesmos e de cristais ou triidrato de acetato de sódio hidratado ou anidro, acetato de potássio ou mistura dos mesmos
NZ508074A (en) Biologically active compositions, and methods for their preparation, comprising a carrier matrix supersaturated with active agent
JPS5687519A (en) Drug pharmaceutical
JPS53130054A (en) Orientation treatment method of liquid crystal cells
EP0667153A4 (en) METHOD FOR PRODUCING A COMPOSITION FOR A MEDICINE IN SOLID FORM.
JPS5646845A (en) Preparation of aromatic amino compound
WO2004100994A3 (de) Werfahren zur herstellung einer stabilen injizierbaren formulierung von schwer löslichen antineoplastischen wirkstoffen